Press Releases

Press Releases

August 2, 2021
CytomX Therapeutics to Present at Upcoming August Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform,
Additional Formats
April 14, 2021
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology
Additional Formats
March 24, 2021
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
SOUTH SAN FRANCISCO, Calif. , March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody ® technology
Additional Formats
Displaying 11 - 20 of 30